What is Diamond Equity’s Estimate for BHST Q1 Earnings?

BioHarvest Sciences Inc. (NASDAQ:BHST) – Stock analysts at Diamond Equity issued their Q1 2026 earnings estimates for BioHarvest Sciences in a research report issued to clients and investors on Thursday, April 3rd. Diamond Equity analyst H. Diamond anticipates that the company will post earnings per share of ($0.01) for the quarter. The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.80) per share. Diamond Equity also issued estimates for BioHarvest Sciences’ Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.03 EPS and Q4 2026 earnings at $0.06 EPS.

Separately, Maxim Group assumed coverage on shares of BioHarvest Sciences in a research report on Wednesday, December 18th. They set a “buy” rating and a $12.00 target price for the company.

BioHarvest Sciences Trading Down 3.5 %

Shares of BHST stock opened at $5.54 on Monday. BioHarvest Sciences has a 1-year low of $5.53 and a 1-year high of $7.38. The firm has a market capitalization of $90.99 million, a PE ratio of -4.44 and a beta of 0.84. The company has a 50-day moving average of $5.70.

BioHarvest Sciences (NASDAQ:BHST) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05). The company had revenue of $7.17 million during the quarter, compared to analyst estimates of $7.24 million.

Institutional Trading of BioHarvest Sciences

A hedge fund recently bought a new stake in BioHarvest Sciences stock. TD Waterhouse Canada Inc. acquired a new stake in BioHarvest Sciences Inc. (NASDAQ:BHST) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 12,042 shares of the company’s stock, valued at approximately $69,000. TD Waterhouse Canada Inc. owned 0.07% of BioHarvest Sciences at the end of the most recent reporting period.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.